MDWD
MediWound Ltd.
Set alert
13.30 USD -0.56 -4.04%
13.24 Day range 13.94
11.85 52-week range 19.37
- YTD
- -27.95%
- 1 year
- -28.30%
- Open
- 13.94
- Prev close
- 13.86
- Mkt cap
- 171.71M
- Vol
- 110.11K
- Avg vol
- 94.03K
- EPS
- -2.17
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.24
- High
- 13.94
- Forward P/E
- -7.96
- Beta
- 0.84
- Short ratio
- 18.59
- Inst. own
- 45.50%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 17.27
- 200-d avg
- 17.21
- 1y target
- 29.00
Key statistics
- Market cap
- 190.66M
- Enterprise value
- 138.07M
- Trailing P/E
- 0.00
- Forward P/E
- -7.96
- PEG ratio
- 0.00
- Price / sales
- 9.47
- Price / book
- 5.16
- EPS (TTM)
- -2.91
- Beta
- 0.84
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -99.17%
- Revenue (TTM)
- 20.14M
- Revenue growth
- 6.10%
- Free cash flow
- -8.42M
- Total cash
- 29.21M
- Total debt
- 6.36M
- Return on equity
- -75.66%
- Shares outstanding
- 10.79M
- Short % of float
- 6.43%
- 50-day average
- 17.27
- 200-day average
- 17.21
Analyst view
Consensus: none
Price target (mean) 29.00 +118.0% upside
Now 13.30
- Target (low)
- 25.00
- Target (mean)
- 29.00
- Target (high)
- 36.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.55667.
Financials — quick view
MDWD Revenue — quarterly 3.09M
MDWD Net income — quarterly -7.39M
MDWD EPS — quarterly -0.57
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 26, 2024 | Sep 1, 2024 | -0.48 | -0.98 | -0.50 | -104.17% |
| Aug 14, 2024 | Jun 1, 2024 | -0.42 | -0.68 | -0.26 | -61.90% |
| May 29, 2024 | Mar 1, 2024 | -0.40 | -0.39 | +0.01 | +2.50% |
| Mar 21, 2024 | Dec 1, 2023 | -0.23 | -0.19 | +0.04 | +17.39% |
| Nov 21, 2023 | Sep 1, 2023 | -0.45 | -0.24 | +0.21 | +46.67% |
| Aug 15, 2023 | Jun 1, 2023 | -0.41 | 0.10 | +0.51 | +124.39% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 27, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 30, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- mediwound.com
News
- MediWound to Report Third Quarter 2026 Financial Results
- Taysha Gene Therapies (NASDAQ:TSHA) versus MediWound (NASDAQ:MDWD) Head to Head Analysis
- MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
- Independent DSMB Recommends MediWound's EscharEx® Phase III VALUE Study Continue Without Modification
- MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Oppenheimer Maintains Outperform on MediWound, Lowers Price Target to $30
- MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript
- MediWound Q2 Earnings Call Highlights
- MediWound Q2 2026 Earnings Call: Complete Transcript
- MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates
Your note
Sign in to keep a note on MDWD — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Investor AB | 6.83% | 872,093 | 15.41M | Sep 29, 2024 |
| Yelin Lapidot Holdings Management Ltd. | 5.88% | 750,743 | 13.27M | Sep 29, 2024 |
| Rosalind Advisors, Inc. | 4.92% | 628,050 | 11.10M | Sep 29, 2024 |
| Blackrock Inc. | 3.39% | 432,996 | 7.65M | Sep 29, 2024 |
| Balyasny Asset Management LLC | 1.30% | 165,736 | 2.93M | Sep 29, 2024 |
| Sargent Investment Group, LLC | 0.92% | 117,192 | 2.07M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 1.62% | 206,380 | 3.65M | Oct 30, 2024 |
| ARK ETF Tr-ARK Israel Innovative Technology ETF | 0.91% | 115,765 | 2.05M | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.64% | 81,744 | 1.44M | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.55% | 70,150 | 1.24M | Oct 30, 2024 |
| Vanguard Russell 2000 Index Fund | 0.25% | 32,376 | 572.08K | Aug 30, 2024 |
| 1290 Fds-1290 Essex Small Cap Growth Fd | 0.17% | 21,233 | 375.19K | Jul 30, 2024 |